Cancer after heart transplant is recognized as a leading cause of morbidity and mortality. A man's clinical course after receiving a heart transplant is described, with emphasis on important clinical considerations in the care of heart transplant recipients.
Get full access to this article
View all access options for this article.
References
1.
TaylorDOEdwardsLBAuroraP. Registry of the International Society for Heart and Lung Transplant: Twenty-Fifth Official Adult Heart Transplant Report—2008. J Heart Lung Transplant.2008;27(9):943–956.
RoithmaierSHaydonAMLoiS. Incidence of malignancies in heart and/or lung transplant recipients: A single-institution experience. J Heart Lung Transplant.2007; 26(8):845–849.
4.
StehlikJEdwardsLBKucheryavayaAY. The Registry of the International Society for Heart and Lung Transplantation: Twenty-Eighth Adult Heart Transplant Report—2011. J Heart Lung Transplant.2011;30(10):1078–1094.
5.
Crespo-LeiroMGAlonso-PulponLde PradaVasquez JA. Malignancy after heart transplantation: Incidence, prognosis and risk factors. Am J Transplant.2008;8(5):1031–1039.
6.
BrewerJDColegioORPhillipsPK. Incidence of and risk factors for skin cancer after heart transplant. Arch Dermatol.2009;145(12):1391–1396.
7.
KellermanLNeugutABurkeBManciniD.Comparison of the incidence of de novo solid malignancies after heart transplantation to that in the general population. Am J Cardiol.2009;103(4):562–566.
8.
SwinnenLJConstazo-NordinMRFisherSG. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med.1990;323(25):1723–1728.
9.
GaoSZChaparroSVPerlrothM. Posttransplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant.2003;22(5):505–514.
10.
PerairaJRSegoviaJFuertesB. Current induction immunosuppression and post-heart transplant lymphoproliferative disorders. Transplant Proc.2003;35(5):2009–2010.
11.
DantalJSoulillouJRJP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med.2005;352(13):1371–1373.
12.
ArichiNKishikawaHNishimuraK. Malignancy following kidney transplantation. Transplant Proc.2008;40(7):2400–2402.
13.
KasiskeBLSnyderJJGilbertsonDTWangC.Cancer after kidney transplantation in the United States. Am J Transplant.2004;4(6):905–913.
14.
HuebnerGKarthausMPethigKFruendMGanserA.Myelodysplastic syndrome and acute myelogenous leukemia secondary to heart transplantation. Transplantation.2000;70(4):688–690.
15.
O'NeillJEdwardsLBTaylorDO. Mycophenolate mofetil and the risk of developing malignancy after orthotopic heart transplantation: Analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant.2006;25(10):1186–1119.
16.
TopilskyYHasinTRaichlinE. Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation. Circulation.2012;125(5):708–720.
17.
CampistolJMDe FijterJWNashanBHoldaasHVitkoSLegendreC.Everolimus and long-term outcomes in renal transplantation. Transplantation.2011;92(3S):S3–S26.
18.
MitaMMMitaARowinskyEK. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther.2003;2(4suppl 1):S169–S177.
19.
KoehlGEAndrassyJGubaM. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation.2004;77(9):1319–1326.
20.
StalloneGSchenaAInfanteB. Sirolimus for Kaposi's sarcoma in renal transplant recipients. N Engl J Med.2005;352(13):1317–1323.
21.
AlberuJPascoeMDCampistolJM; for the Sirolimus CONVERT Trial Study Group. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation.2011;92(3):303–310.
